The European Medicines Agency found no link between the Oxford / AstraZeneca vaccine and the previous report of rare blood clots, two weeks after assuring first EU members as EU members, a growing number of countries have announced new restrictions on the use of JAB.
Although the United Kingdom and Austria have not imposed any sanctions, France, Sweden, Finland, Canada and more recently Germany Advised minors to avoid shots. It is still suspended in Norway and Denmark.
The EMA, the World Health Organization and the UK’s Medicines and Health Care Products Regulatory Agency have all said that the benefits of the vaccine outweigh any potential risks. But a rare combination of blood-related symptoms in a small number of people means some governments are moving more cautiously.
Why are some governments still worried?
The main condition that causes alarm formation is called cerebral venous sinus thrombosis (CVST), when blood clots form in the blood vessels from the brain, a potentially fatal complication. In case of anxiety, it has been combined with something called thrombocytopenia where a patient also presents abnormally low levels of platelets resulting in heavy bleeding.
In Norway, health officials say at least six of Jaber’s 120,000 recipients have had such incidents, four of whom have died. In Germany, 31 cases were reported after 2.m million vaccinations, including 29 women between the ages of 20 and 633 and two men between the ages of 36 and 5. Nine of them died.
UK regulator on Thursday Announcement It identified 25 more cases, with rare cases in Britain standing at 30 out of a total of 18.1 million people receiving estrogena shots – roughly one in every 600,000 recipients.
One Guess whatA group of researchers in Germany have been told that the AstraZeneca vaccine can cause excessive immunity in some people, causing them to produce antibodies targeting blood platelets.
A rare combination of blood clots and low platelet counts typically affects about 100,000 people a year in Germany, with one researcher reporting that 31 cases identified within two weeks of being vaccinated with the Astrageneca vaccine indicated a 10-fold higher incidence rate.
“It’s not just numbers, it’s a process – it’s like a puzzle where evidence comes from different angles that it’s something unusual,” said Johannes Oldenberg, a professor of transfusion medicine at Sister University, who helped develop the hypothesis. Oldenberg said he believed that “probably these events originated from the AstraZeneca vaccine.”
Could age be a factor?
If the vaccine causes this adverse reaction, the level of incidence in different countries may result in different age profiles of those who have received the vaccine, some experts say.
Mainland Europe, for example, has vaccinated more people under the age of 60 than the United Kingdom, who first vaccinated health workers and the elderly using a division of Fizer and AstraZeneca shots.
Saad Shakir, director of the Drug Safety Research Unit in Southampton, said: “As the AstraZeneca vaccine continues to be studied, it is a complex problem that has spread across the UK using different vaccines at different ages across the UK. Some younger people with the system have actions that increase the rare immunity to the vaccine
It is also true, experts say, that young people and especially young women are generally more susceptible to this type of rare blood clotting. In the general population the symptoms are almost threefold More common in women Compared to men and those who are affected, their medieval age is 33.
However, the EMA on Wednesday said it had not yet been able to identify any evidence of a link between blood clotting and “specific risk factors, including age, gender or previous history.”
“Right now, at this stage of our investigation, the link is possible and we can’t say more than that at the moment,” said EMA chief Emer Cook. “There is no evidence to support limiting the use of this vaccine in any population.” MHRA did not disclose the age or gender of the new cases identified in the UK.
The differences between the EMA and the position of some European scientists give rise to conflicting national consultations at different times and sometimes about who should and should not be shot.
Various tips about the AstraZeneca vaccine
France and Canada are limiting this vaccine to humans More than 55
Germany is only recommending it to people More than 60
Italy is restricting jobs among the people Below 80
There are Austria and the United Kingdom No limitations In place
Sweden and Finland are using it only for them More than 65
The shot is in Norway and Denmark Suspended At least until mid-April
Switzerland is still there Not allowed Absolutely
Has the same thing happened with other vaccines?
Not much. In the UK, at least two CVST reports have been published among people receiving the Pfizer vaccine. However, the MHRA said on Thursday that the CVST cases of AstraZeneca job recipients did not match those with low platelet counts. Doses of more than 12 m of the shot were administered.
Oldenberg of Forest University said he was unaware of any such incidents among people who had received the Covid-19 vaccine in Europe, especially those who had received shots made by Pfizer and Moderna.
A member of the Joint Committee on Immunization and Vaccination (JCVI) who advised the UK government that it could be “premature” to specify that the Pfizer shot was not the cause of similar problems “[Experts in Europe] The AstraZeneca vaccine has been looked at more closely so they have found more, ”said a committee member.
What is the UK doing?
UK officials say there is not enough evidence at the moment to make any changes to vaccination policy. Even if a causal link is established, some UK-based experts say it would be wise to continue vaccination as blood clotting has been found to be very rare.
“The benefits of vaccines against Kovid-19 can outweigh any risks and you should continue to receive the vaccine if invited to do so,” the MHRA said Thursday after releasing details of a newly recorded case of blood clots with low platelets. Count
The JCVI member said: “The UK’s position is largely that AstraZeneca and Pfizer are probably safer, or the risks are so low that they are greatly increased by the benefits, so we should continue to use them.”
The possibility was that in the future there could be a lawsuit to “correct their use for young people but we are far from it,” the person added, describing European measures as “premature”.
Germany’s Hollandeberg has said he agrees with the UK’s decision, although he strongly believes the AstraZeneca shot caused symptoms.
“If I had a choice between vaccinating AstraZeneca immediately or waiting four weeks for modernization, I would choose the AstraZeneca vaccine, because the four-week protection is much more than this risk.”
Oxford University and AstraZeneca say their tests show the vaccine is safe and effective, and they have been monitoring side effects since the shot was launched.